top of page

Braeburn Pharmaceuticals and Camurus present positive data from opioid use disorder clinical studies

Braeburn Pharmaceuticals and Camurus presented data from three clinical studies on CAM2038, an investigational injectable medication administered to opioid use disorder participants, at the annual meeting of the International Society of Addiction Medicine (ISAM) and the Canadian Society of Addiction Medicine (CSAM).




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page